News | April 15, 2025
Biocon Biologics secures market entry date for Yesafili in US
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
The product will be launched in Q1FY26
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
The company expects to launch this product through its marketing partner in the near future
The consignment of USFDA qualified Metformin (1000mg) was received by the province of Mendoza for distribution in the public health system
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the US by Glenmark Therapeutics, USA.
Apitoria Pharma’s API manufacturing facility classified as VAI by USFDA
Subscribe To Our Newsletter & Stay Updated
